The SAVI SCOUT surgical guidance system has been adopted by hospitals throughout the country. Brought to you by the same team behind the SAVI brachytherapy applicator, SCOUT
is a FDA-cleared medical device used to provide tumor localization and real-time guidance during breast surgery.
If you would like to be kept up to date on the latest information and updates regarding SCOUT, including details on clinical experience and product availability, you are invited
to join the SCOUT Report® community.
er of Excellence in APBI!
Learn about becoming a Center of Excellence and find ways to grow your
APBI program by reaching out to referring physicians and women in the community.
Milestone Data Published Validating APBI Equivalence to WBI
Clinicians have long awaited Level 1 clinical evidence to support the use of accelerated treatment with brachytherapy, an approach that is kinder to the patient, less time consuming and targets only the tissue at risk. In a recent interview with Oncology Central, Frank Vicini, MD, Chief Academic Officer for Michigan Healthcare Professionals and 21st Century Oncology and Professor of Radiation Oncology, discusses data from a landmark study that indicate APBI brachytherapy leads to equivalent overall survival rates, and equivalent local and regional cancer control rates, as compared with WBI after breast conserving surgery for selected patients with early stage breast cancers.
The GEC-ESTRO accelerated partial breast irradiation (APBI) trial is the largest prospective, randomized Phase III multicenter trial to directly evaluate the role of multicatheter interstitial brachytherapy alone, compared with whole breast irradiation (WBI), in a defined low-risk group of invasive breast cancer or ductal carcinoma in situ (DCIS).
Results demonstrated that APBI brachytherapy leads to equivalent overall survival rates, and equivalent local and regional cancer control rates, as compared with WBI after breast conserving surgery for selected patients with early stage breast cancers.
The published results with intraoperative single-fraction radiotherapy either with electrons (ELIOT-trial) or with soft X-rays (TARGIT trial) proved the inferiority of single fraction IORT compared to WBI.
Accelerated Partial Breast Irradiation (APBI) Consensus Statement:
Update of an ASTRO Evidence-Based Consensus Statement
ASTRO is currently seeking comments on the draft update of Acceleration Partial Breast Irradiation Consensus Statement (APBI); the deadline for comments is 4:59 p.m. Eastern time March 14, 2016.
Highlights of the proposed update include:
- Lowering the age in the ‘suitability group’ from 60 to 50 years of age and adding post-menopausal status for patients aged 50-59
- Lowering the age in the ‘cautionary group’ to 40 years for patients who meet all other elements of suitability.
- Recommendations relative to DCIS include categorizing patients with low-risk DCIS as per RTOG 9804 criteria in the “suitable” group.
- Recommendations for the use of IORT for breast cancer patients outside of a clinical trial include: counseling patients regarding the higher risk of ipsilateral breast tumor recurrence (IBTR) with IORT compared to whole breast irradiation
- IORT with low-energy x-rays is not encouraged at this time due to short follow up and limitations of the available literature
- Restricting electron beam IORT, when used, to women age ≥50 years with primary invasive breast cancer size < 2 cm and T1 N0, hormone sensitive, grade 1-2 tumors,
A First-Hand Comparison of Breast Cancer Treatment: 2000 vs. 2015
Rochelle Colon has battled b
reast cancer twice –
once in 2000, and again in 2015. She is amazed at how much medical technology has advanced over those 15 years, and how much better her patient experience was the second time around.
In 2000, Rochelle was diagnosed with an invasive, ductal carcinoma in her left breast.
Rochelle Colon, Retired English
Teacher and Breast Cancer Survivor
After a lumpectomy and a subsequent re-excision surgery, Rochelle endured six grueling weeks of traditional radiation therapy, which caused an adverse skin reaction and other unpleasant side effects.
In 2015 during a routine mammogram, non-invasive ductal carcinoma in-situ (DCIS) was discovered in her right breast. A lumpectomy was performed using the SAVI SCOUT® breast localization and surgical guidance system, followed by five days of radiation using the SAVI® brachytherapy applicator. Today, once again cancer-free, Rochelle is back to living life on her terms.
“I’m a big fan of SAVI SCOUT! That implant is a miracle! With SAVI SCOUT, Dr. Anglin
[breast surgeon Beth Anglin, M.D., FACS Medical Center of Plano] was able to pinpoint the tumor immediately. There was no need for a second surgery.”
“Honestly my bigger fears this time around had to do with all the side effects – the lymphedema, the radiation burns. I’m so grateful I was able to receive the SAVI Brachy treatment. It made it 100% easier for me. I didn’t have such a long recovery period, it wasn’t painful, and there was no lymphedema. I would definitely choose the SAVI treatment again rather than weeks of traditional radiation – if I ever have to face breast cancer again.”
To read the entire transcript from our interview with Rochelle, click here